Sugi Predict

Sugi Predict / Compounds / SCHEMBL599471

SCHEMBL599471

SCHEMBL599471

Cc1cc2cc3c(C)cc(=O)oc3cc2o1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 12/20 0.57
▸ ALDH1A1 P00352 9/20 0.57
▸ HPGD P15428 7/20 0.56
▸ HSD17B10 Q99714 7/20 0.56
▸ MCL1 Q07820 4/20 0.56
▸ CYP3A4 P08684 2/20 0.56
▸ AKR1B1 P15121 2/20 0.56
▸ THRB P10828 1/20 0.56
▸ MAOA P21397 4/20 0.54
▸ CYP1A2 P05177 3/20 0.54
▸ HTR2C P28335 1/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ ADORA2A P29274 1/20 0.54
▸ DYRK1A Q13627 1/20 0.54
▸ GAA P10253 5/20 0.51
▸ TSHR P16473 1/20 0.51
▸ GLA P06280 4/20 0.51
▸ CASP1 P29466 3/20 0.51
▸ CASP7 P55210 3/20 0.51
▸ HSP90AA1 P07900 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18788977 0.80 KDM4E (0.51) KDM4EALDH1A1HPGDHSD17B10MCL1
SCHEMBL21166585 0.78 DYRK1A (0.40) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL18788976 0.78 ALDH1A1 (0.50) KDM4EALDH1A1HPGDHSD17B10MCL1
SCHEMBL18788975 0.78 KDM4E (0.51) KDM4EALDH1A1HPGDHSD17B10MCL1
SCHEMBL20278636 0.77 MAOA (0.55) KDM4EALDH1A1HPGDHSD17B10MCL1
4,6,7-Trimethyl-2H-Chromen-2-One SCHEMBL19049403 0.77 KDM4E (0.68) KDM4EALDH1A1HPGDHSD17B10MCL1
SCHEMBL600311 0.76 KDM4E (0.58) KDM4EALDH1A1HPGDHSD17B10MCL1
SCHEMBL11194490 0.74 GAA (0.64) KDM4EALDH1A1HPGDHSD17B10MCL1
SCHEMBL4419972 0.73 DYRK1A (0.45) KDM4EALDH1A1HPGDHSD17B10CYP3A4
SCHEMBL606446 0.73 KDM4E (0.66) KDM4EALDH1A1HPGDHSD17B10MCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 195 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9309315-B2 Therapy with CD4 binding peptides and radiation GENMAB A/S (DK) 2016-04-12 — — US claimed
EP-1951303-B1 THERAPY WITH ANTI-CD4 ANTIBODIES AND RADIATION GENMAB AS (DK) 2011-02-02 — — EP claimed
US-20100015134-A1 Therapy With CD4 Binding Peptides and Radiation GENMAB A/S 2010-01-21 — — US claimed
EP-1951303-A2 THERAPY WITH CD4 BINDING PEPTIDES AND RADIATION Genmab A/S (DK) 2008-08-06 — — EP claimed
WO-2007019865-A2 THERAPY WITH CD4 BINDING PEPTIDES AND RADIATION GENMAB A/S (DK) 2007-02-22 — — WO claimed
US-20060252674-A1 Methods for pretreating a subject with extracorporeal photopheresis THERAKOS, INC. 2006-11-09 — — US claimed
EP-1674095-A1 Phototherapy compositions OMJ Ireland Limited (PR) 2006-06-28 — — EP claimed
US-20060134031-A1 Phototherapy compositions and methods MALLINCKRODT ENTERPRISES LLC 2006-06-22 — — US claimed
EP-0579784-B1 METHOD FOR PREVENTING RESTENOSIS FOLLOWING RECONFIGURATION OF BODY VESSELS ADVANCED RES & TECH INST (US) 1999-11-10 — — EP claimed
EP-0661920-B1 THE USE OF PSORALEN COMPOUNDS TO INHIBIT RESTENOSIS FOLLOWING ANGIOPLASTY BISACCIA EMIL (US) 1999-04-14 — — EP claimed
WO-1993011657-A2 THE USE OF PSORALEN COMPOUNDS TO INHIBIT RESTENOSIS FOLLOWING ANGIOPLASTY BISACCIA EMIL (US) 1993-06-24 — — WO claimed
US-5219882-A Treatment methods for lymes disease and associated debilitating conditions BISACCIA EMIL (US) 1993-06-15 — — US claimed
WO-1992018122-A1 METHOD FOR PREVENTING RESTENOSIS FOLLOWING RECONFIGURATION OF BODY VESSELS INDIANA UNIVERSITY FOUNDATION (US) 1992-10-29 — — WO claimed
EP-0453497-A4 TREATMENT METHODS AND VACCINES — 1992-10-07 — — EP claimed
US-5116864-A Method for preventing restenosis following reconfiguration of body vessels INDIANA UNIVERSITY FOUNDATION (US) 1992-05-26 — — US claimed
EP-0453497-A1 TREATMENT METHODS AND VACCINES BISACCIA, Emil (US) 1991-10-30 — — EP claimed
US-4960408-A ADMINISTERING A PSORALEN COMPOUND, EXPOSING TO ELECTROMAGNETIC RADIATION KLAINER ALBERT S (US) 1990-10-02 — — US claimed
US-4950770-A Psoralens aminomethylation ELDER PHARMACEUTICALS, INC. (US) 1990-08-21 — — US claimed
WO-1990007952-A1 TREATMENT METHODS AND VACCINES BISACCIA EMIL (US) 1990-07-26 — — WO claimed
US-4748120-A Photochemical decontamination treatment of whole blood or blood components DIAMOND SCIENTIFIC CO. (US) 1988-05-31 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060134031-A1 Phototherapy compositions and methods VCL, TYR, TTPA KDM4E 4478/4885ALDH1A1 1344/4885HPGD 2393/4885
US-20100015134-A1 Therapy With CD4 Binding Peptides and Radiation CD4, CD74, SELPLG KDM4E 4522/4885ALDH1A1 4414/4885HPGD 3137/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.